‘Non-criteria’ neurologic manifestations of antiphospholipid syndrome: A hidden kingdom to be discovered

CNS and Neurological Disorders - Drug Targets

Volumn 15, Issue 10, 2016, Pages 1253-1265

  Islam, Md Asiful ^a   Alam, Fahmida ^a   Kamal, Mohammad Amjad ^b,c,d   Wong, Kah Keng ^a   Sasongko, Teguh Haryo ^a   Gan, Siew Hua ^a  

^a SCHOOL OF MEDICAL SCIENCES   (Malaysia)

^b KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^c Enzymoics   (Australia)

^d Novel Global Community Educational Foundation   (Australia)

Author keywords

Antiphospholipid antibodies; Antiphospholipid syndrome; Central nervous system; Neurological manifestations; Pathophysiology; Treatment

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; AZATHIOPRINE; BETA2 GLYCOPROTEIN 1; CARDIOLIPIN ANTIBODY; DIPYRIDAMOLE; ENOXAPARIN; GLUCOCORTICOID; HALOPERIDOL; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LAMOTRIGINE; LUPUS ANTICOAGULANT; NEUROLEPTIC AGENT; PHENPROCOUMON; PHENYTOIN; PHOSPHOLIPID ANTIBODY; PREDNISOLONE; QUETIAPINE; STEROID; WARFARIN;

ANTIPHOSPHOLIPID SYNDROME; BIPOLAR DISORDER; CEREBROVASCULAR ACCIDENT; CHOREA; COGNITIVE DEFECT; DEMENTIA; DYSTONIA; EPILEPSY; GILLES DE LA TOURETTE SYNDROME; HEADACHE; HUMAN; LEUKOENCEPHALOPATHY; MIGRAINE; MOTOR DYSFUNCTION; MULTIPLE SCLEROSIS; MYELITIS; NONHUMAN; OBSESSIVE COMPULSIVE DISORDER; PARKINSONISM; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHEUMATIC FEVER; TRANSIENT GLOBAL AMNESIA; TRANSIENT ISCHEMIC ATTACK; ANIMAL; BLOOD; COMPLICATION; DISEASE MODEL; IMMUNOLOGY; METABOLISM; NERVOUS SYSTEM DISEASES;

ANIMALS; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; DISEASE MODELS, ANIMAL; HUMANS; NERVOUS SYSTEM DISEASES;

EID: 84995629557     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/1871527315666160920122750     Document Type: Review

References (139)

1. Hughes G. Thrombosis, abortion, cerebral disease, and the lupus anticoagulant. Br Med J 1983; 287: 1088.
2. Miyakis S, Lockshin M, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295-306.
3. Asherson RA, Khamashta MA, Ordi-Ros J, et al. The “ primary” antiphospholipid syndrome: major clinical and serological features. Medicine (Baltimore) 1989; 68: 366-74.
4. Alarcon-Segovia D, Deleze M, Oria CV, et al. Antiphospholipid Antibodies and the Antiphospholipid Syndrome in Systemic Lupus Erythematosus A Prospective Analysis of 500 Consecutive Patients. Medicine (Baltimore) 1989; 68: 353-65.
5. Cervera R, Bucciarelli S, Plasin MA, et al. Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of a series of 280 patients from the “CAPS Registry”. J Autoimmun 2009; 32: 240-5.
6. Cervera R, Piette JC, Font J, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 2002; 46: 1019-27.
7. Gris JC, Brenner B. Antiphospholipid antibodies: neuropsychiatric presentations. Semin Thromb Hemost 2013; 39: 935-42.
8. Gris JC, Nobile B, Bouvier S. Neuropsychiatric presentations of antiphospholipid antibodies. Thromb Res 2015; 135: S56-9.
9. Raza H, Epstein SA, Rosenstein DL. Mania: psychiatric manifestations of the antiphospholipid syndrome. Psychosomatics 2008; 49: 438-41.
10. Gomez-Puerta J, Cervera R, Calvo L, et al. Dementia associated with the antiphospholipid syndrome: clinical and radiological characteristics of 30 patients. Rheumatology 2005; 44: 95-9.
11. da Silva F, de Carvalho J. Rheumatic Fever Associated with Antiphospholipid Syndrome: Systematic Review. J Immunol Res 2014; 2014: 1-6.
12. Stojanovich L, Kontic M, Smiljanic D, Djokovic A, Stamenkovic B, Marisavljevic D. Association between non-thrombotic neurological and cardiac manifestations in patients with antiphospholipid syndrome. Clin Exp Rheumatol 2013; 31: 756-60.
13. Karabekiroğlu A, Yılmaz A, Kocamanoğlu B. Acute Psychotic Symptoms: A manifestation of Antiphospholipid Syndrome or Infarction of Corpus Callosum. Psychiatr Danubina 2015; 27: 280.
14. Fukui T, Kawamura M, Hasegawa Y, Kato T, Kaga E. Multiple cognitive impairments associated with systemic lupus erythematosus and antiphospholipid antibody syndrome: A form of progressive vascular dementia? Eur Neurol 2000; 43: 115-6.
15. Zardi E, Zardi D, Lazarevic Z, et al. Transient global amnesia as the first symptom of primary antiphospholipid syndrome: a case report. Int J Immunopathol Pharmacol 2012; 25: 275-80.
16. Huang YC, Lyu RK, Chen ST, Chu YC, Wu YR. Parkinsonism in a patient with antiphospholipid syndrome-Case report and literature review. J Neurol Sci 2008; 267: 166-9.
17. Carecchio M, Comi C, Varrasi C, et al. Complex movement disorders in primary antiphospholipid syndrome: A case report. J Neurol Sci 2009; 281: 101-3.
18. Sanna G, D’Cruz D, Cuadrado MJ. Cerebral manifestations in the antiphospholipid (Hughes) syndrome. Rheum Dis Clin N Am 2006; 32: 465-90.
19. Espinosa G, Cervera R, Font J, Shoenfeld Y. Antiphospholipid syndrome: pathogenic mechanisms. Autoimmun Rev 2003; 2: 86-93.
20. Sanna G, Bertolaccini M, Cuadrado M, Khamashta M, Hughes G. Central nervous system involvement in the antiphospholipid (Hughes) syndrome. Rheumatology 2003; 42: 200-13.
21. Chapman J, Rand J, Brey R, et al. Non-stroke neurological syndromes associated with antiphospholipid antibodies: evaluation of clinical and experimental studies. Lupus 2003; 12: 514-7.
22. Arnson Y, Shoenfeld Y, Alon E, Amital H. The antiphospholipid syndrome as a neurological disease. Semin Arthritis Rheum 2010; 40(2): 97-108.
23. Rodrigues CE, Carvalho JF, Shoenfeld Y. Neurological manifestations of antiphospholipid syndrome. Eur J Clin Invest 2010; 40: 350-9.
24. Cavestro C, Micca G, Molinari F, et al. Migraineurs show a high prevalence of antiphospholipid antibodies. J Thromb Haemost 2011; 9: 1350-4.
25. Szmyrka-Kaczmarek M, Pokryszko-Dragan A, Pawlik B, et al. Antinuclear and antiphospholipid antibodies in patients with multiple sclerosis. Lupus 2012; 21: 412-20.
26. Stosic M, Ambrus J, Garg N, et al. MRI characteristics of patients with antiphospholipid syndrome and multiple sclerosis. J Neurol 2010; 257: 63-71.
27. Toren P, Toren A, Weizman A, et al. Tourette’s disorder: is there an association with the antiphospholipid syndrome? Biol Psychiatry 1994; 35: 495-8.
28. Singer HS, Krumholz A, Giuliano J, Kiessling LS. Antiphospholipid antibodies: an epiphenomenon in Tourette syndrome. Mov Disord 1997; 12: 738-42.
29. Liu E, Robertson RL, du Plessis A, Pomeroy SL. Basal ganglia germinoma with progressive cerebral hemiatrophy. Pediatr Neurol 1999; 20: 312-4.
30. Hughes GR. Hughes syndrome (the antiphospholipid syndrome): ten clinical lessons. Autoimmun Rev 2008; 7: 262-6.
31. Shoenfeld Y, Lev S, Blatt I, et al. Features associated with epilepsy in the antiphospholipid syndrome. J Rheumatol 2004; 31: 1344-8.
32. Krause I, Lev S, Fraser A, et al. Close association between valvar heart disease and central nervous system manifestations in the antiphospholipid syndrome. Ann Rheum Dis 2005; 64: 1490-3.
33. Toubi E, Krause I, Fraser A, et al. Livedo reticularis is a marker for predicting multi-system thrombosis in antiphospholipid syndrome. Clin Exp Rheumatol 2005; 23: 499.
34. Appenzeller S, Yeh S, Maruyama M, Barros SM, de Carvalho JF. Chorea in primary antiphospholipid syndrome is associated with rheumatic fever. Rheumatol Int 2012; 32: 2857-61.
35. Avari JN, Young RC. A patient with bipolar disorder and antiphospholipid syndrome. J Geriatr Psychiatry Neurol 2012; 25: 26-8.
36. Shalaby M, Alhumayed S, Alshehri A. Paediatric case report: primary antiphospholipid syndrome presented with non_thrombotic neurological picture psychosis; treat by antidepressants alone? Int J Rheum Dis 2009; 12: 170-3.
37. Zhu DS, Fu J, Zhang Y, et al. Neurological antiphospholipid syndrome: Clinical, neuroimaging, and pathological characteristics. J Neurol Sci 2014; 346: 138-44.
38. Losonczy LI, Johnson B, Sidhu J, Li J, Feeney CM. Seronegative Catastrophic Antiphospholipid Syndrome in a Young Female Presenting with a Headache. J Emerg Med 2015; 48: 294-7.
39. Saraf SS, Patel YP, Desai A, Desai UR. Catastrophic Antiphospholipid Syndrome Presenting as Bilateral Central Retinal Artery Occlusions. Case Rep Ophthalmol Med 2015; 2015: 206906.
40. Cervera R, Boffa M, Khamashta M, Hughes G. The Euro-Phospholipid project: epidemiology of the antiphospholipid syndrome in Europe. Lupus 2009; 18: 889-93.
41. Garcia-Carrasco M, Galarza C, Gomez-Ponce M, et al. Antiphospholipid syndrome in Latin American patients: clinical and immunologic characteristics and comparison with European patients. Lupus 2007; 16: 366-73.
42. Abreu MM, Danowski A, Wahl DG, et al. The relevance of “noncriteria” clinical manifestations of antiphospholipid syndrome: 14th International Congress on Antiphospholipid Antibodies Technical Task Force Report on Antiphospholipid Syndrome Clinical Features. Autoimmun Rev 2015; 14: 401-14.
43. Arnaud L, Mathian A, Devilliers H, et al. Patient-level analysis of five international cohorts further confirms the efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies. Autoimmun Rev 2015; 14: 192-200.
44. Tănăsescu R, Nicolau A, Caraiola S, et al. Antiphospholipid antibodies and migraine: a retrospective study of 428 patients with inflammatory connective tissue diseases. Rom J Intern Med 2006; 45: 355-63.
45. Williams F, Cherkas L, Bertolaccini M, et al. Migraine and antiphospholipid antibodies: no association found in migraine_discordant monozygotic twins. Cephalalgia 2008; 28: 1048-52.
46. Stojanovich L, Kontic M, Djokovic A, et al. Association between systemic non-criteria APS manifestations and antibody type and level: results from the Serbian national cohort study. Clin Exp Rheumatol 2013; 31: 234-42.
47. Anderson IM, Haddad PM, Scott J. Bipolar disorder. BMJ 2012; 2012: 345.
48. Hirschfeld RM, Weissman MM. Risk factors for major depression and bipolar disorder, 5th ed. Lippincott Williams and Wilkins: Philadelphia, USA, 2002.
49. Borchers AT, Gershwin ME. Transverse myelitis. Autoimmun Rev 2012; 11: 231-48.
50. Bertolaccini ML, Khamashta MA, Hughes GR. Diagnosis of antiphospholipid syndrome. Nat Clin Pract Rheumatol 2005; 1: 40-6.
51. Frohman EM, Wingerchuk DM. Transverse myelitis. N Engl J Med 2010; 363: 564-72.
52. Harris E, Gharavi A, Mackworth-Young C, Patel B, Derue G, Hughes G. Lupoid sclerosis: a possible pathogenetic role for antiphospholipid antibodies. Ann Rheum Dis 1985; 44: 281-3.
53. Tristano AG. Autoimmune diseases associated with transverse myelitis. Invest Clin 2009; 50: 251-70.
54. Rodrigues CEM, de Carvalho JF. Clinical, radiologic, and therapeutic analysis of 14 patients with transverse myelitis associated with antiphospholipid syndrome: report of 4 cases and review of the literature. Semin Arthritis Rheum 2011; 40(4): 349-57.
55. D’Cruz DP, Mellor-Pita S, Joven B, et al. Transverse myelitis as the first manifestation of systemic lupus erythematosus or lupuslike disease: good functional outcome and relevance of antiphospholipid antibodies. J Rheumatol 2004; 31: 280-5.
56. Mok CC, Lau CS, Chan E, Wong R. Acute transverse myelopathy in systemic lupus erythematosus: clinical presentation, treatment, and outcome. J Rheumatol 1998; 25: 467-73.
57. Lavalle C, Pizarro S, Drenkard C, Sanchez-Guerrero J, Alarcon-Segovia D. Transverse myelitis: a manifestation of systemic lupus erythematosus strongly associated with antiphospholipid antibodies. J Rheumatol 1990; 17: 34-7.
58. Burns A, Iliffe S. Dementia. BMJ 2009; 338: b75.
59. Roman GC. Vascular dementia: distinguishing characteristics, treatment, and prevention. J Am Geriatr Soc 2003; 51: S296-304.
60. Mosek A, Yust I, Treves T, Vardinon N, Korczyn A, Chapman J. Dementia and antiphospholipid antibodies. Dement Geriatr Cogn Disord 2000; 11: 36-8.
61. Juby A, Davis P, Genge T, McElhaney J. Anticardiolipin antibodies in two elderly subpopulations. Lupus 1995; 4: 482-5.
62. Chapman J, Abu-Katash M, Inzelberg R, et al. Prevalence and clinical features of dementia associated with the antiphospholipid syndrome and circulating anticoagulants. J Neurol Sci 2002; 203: 81-4.
63. Duval A, Darnige L, Glowacki F, et al. Livedo, dementia, thrombocytopenia, and endotheliitis without antiphospholipid antibodies: Seronegative antiphospholipid-like syndrome. J Am Acad Dermatol 2009; 61: 1076-8.
64. Friedman JH. Dementia, ataxia and parkinsonism associated with the antiphospholipid syndrome. Parkinsonism Relat Disord 2011; 17: 215-6.
65. Walker RH. Differential diagnosis of chorea. Curr Neurol Neurosci Rep 2011; 11: 385-95.
66. Sanna G, Bertolaccini ML, Hughes GR. Hughes syndrome, the antiphospholipid syndrome: a new chapter in neurology. Ann NY Acad Sci 2005; 1051: 465-86.
67. Cervera R, Asherson RA, Font J, et al. Chorea in the antiphospholipid syndrome. Clinical, radiologic, and immunologic characteristics of 50 patients from our clinics and the recent literature. Medicine (Baltimore) 1997; 76: 203-12.
68. Katzav A, Chapman J, Shoenfeld Y. CNS dysfunction in the antiphospholipid syndrome. Lupus 2003; 12: 903-7.
69. Sunden-Cullberg J, Tedroff J, Aquilonius SM. Reversible chorea in primary antiphospholipid syndrome. Mov Disord 1998; 13: 147-9.
70. Kiechl-Kohlendorfer U, Ellemunter H, Kiechl S. Chorea as the presenting clinical feature of primary antiphospholipid syndrome in childhood. Neuropediatrics 1999; 30: 96-8.
71. Avčin T, Cimaz R, Silverman ED, et al. Pediatric antiphospholipid syndrome: clinical and immunologic features of 121 patients in an international registry. Pediatrics 2008; 122: e1100-7.
72. Dale RC, Yin K, Ding A, et al. Antibody binding to neuronal surface in movement disorders associated with lupus and antiphospholipid antibodies. Dev Med Child Neurol 2011; 53: 522-8.
73. Fung V, Yiannikas C, Sue C, Yiannikas J, Herkes G, Crimmins D. Is Sydenham’s chorea an antiphospholipid syndrome? J Clin Neurosci 1998; 5: 115-8.
74. Schwarzbach CJ, Schmitt WH, Szabo K, Bazner H, Hennerici MG, Blahak C. Chorea in a patient with cryopyrin-associated periodic syndrome. Neurology 2016; 86: 241-4.
75. Safarpour D, Buckingham S, Jabbari B. Chorea Associated with High Titers of Antiphospholipid Antibodies in the Absence of Antiphospholipid Antibody Syndrome. Tremor Other Hyperkinet Mov 2015; 5: 1-5.
76. Chang BS, Lowenstein DH. Epilepsy. N Engl J Med 2003; 349: 1257-66.
77. Fisher RS, Boas, Wv E, Blume W, et al. Epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia 2005; 46: 470-2.
78. Eriksson K, Peltola J, Keranen T, Haapala A, Koivikko M. High prevalence of antiphospholipid antibodies in children with epilepsy: a controlled study of 50 cases. Epilepsy Res 2001; 46: 129-37.
79. Ranua J, Luoma K, Peltola J, et al. Anticardiolipin and antinuclear antibodies in epilepsy-a population-based cross-sectional study. Epilepsy Res 2004; 58: 13-8.
80. Frohman EM, Racke MK, Raine CS. Multiple sclerosis-the plaque and its pathogenesis. N Engl J Med 2006; 354: 942-55.
81. Hauser SL, Oksenberg JR. The neurobiology of multiple sclerosis: genes, inflammation, and neurodegeneration. Neuron 2006; 52: 61-76.
82. Koudriavtseva T, D’Agosto G, Mandoj C, Sperduti I, Cordiali-Fei P. High frequency of antiphospholipid antibodies in relapse of multiple sclerosis: a possible indicator of inflammatory–thrombotic processes. Neurol Sci 2014; 35: 1737-41.
83. Bidot CJ, Horstman LL, Jy W, et al. Clinical and neuroimaging correlates of antiphospholipid antibodies in multiple sclerosis: a preliminary study. BMC Neurol 2007; 7: 1.
84. Garg N, Zivadinov R, Ramanathan M, et al. Clinical and MRI correlates of autoreactive antibodies in multiple sclerosis patients. J Neuroimmunol 2007; 187: 159-65.
85. Bebbington P. Unravelling psychosis: psychosocial epidemiology, mechanism, and meaning. Shanghai Arch Psychiatry 2015; 27: 70.
86. Kurtz G, Muller N. The antiphospholipid syndrome and psychosis. Am J Psychiatry 1994; 151(12): 1841-2.
87. del Rio-Casanova L, Paz-Silva E, Requena-Caballero I, et al. Psychosis as debut of antiphospholipid syndrome. Rev Neurol 2014; 58: 500-4.
88. Cardinal RN, Shah DN, Edwards CJ, Hughes GR, Fernandez-Egea E. Psychosis and catatonia as a first presentation of antiphospholipid syndrome. Br J Psychiatry 2009; 195: 272.
89. Schwartz M, Rochas M, Weller B, et al. High association of anticardiolipin antibodies with psychosis. J Clin Psychiatry 1998; 59: 1478-23.
90. Sokol DK, O’Brien RS, Wagenknecht DR, Rao T, McIntyre JA. Antiphospholipid antibodies in blood and cerebrospinal fluids of patients with psychosis. J Neuroimmunol 2007; 190: 151-6.
91. Erkan D, Lockshin M. Non-criteria manifestations of antiphospholipid syndrome. Lupus 2010; 19: 424-7.
92. Jacobson MW, Rapport LJ, Keenan PA, Coleman RD, Tietjen GE. Neuropsychological deficits associated with antiphospholipid antibodies. J Clin Exp Neuropsychol 1999; 21: 251-64.
93. Tektonidou MG, Varsou N, Kotoulas G, Antoniou A, Moutsopoulos HM. Cognitive deficits in patients with antiphospholipid syndrome: association with clinical, laboratory, and brain magnetic resonance imaging findings. Arch Intern Med 2006; 166: 2278-84.
94. Aharon-Peretz J, Brenner B, Amyel-Zvi E, Metz L, Hemli JA. Neurocognitive Dysfunction in the Antiphospholipid Antibody Syndrome (APS). Cogn Behav Neurol 1996; 9: 123-6.
95. Schmidt R, Auer-Grumbach P, Fazekas F, Offenbacher H, Kapeller P. Anticardiolipin antibodies in normal subjects neuropsychological correlates and MRI findings. Stroke 1995; 26: 749-54.
96. Singer HS. Tourette syndrome and other tic disorders. Handb Clin Neurol 2011; 100: 641-57.
97. Seijo-Martinez M, Mosquera-Martinez J, Romero-Yuste S, Cruz-Martinez J. Ischemic Stroke and Epilepsy in a Patient with Tourette´ s Syndrome: Association with the Antiphospholipid Syndrome and Good Response to Levetiracetam. Open Neurol J 2008; 2: 32-4.
98. Baizabal-Carvallo J, Jankovic J. Parkinsonism, movement disorders and genetics in frontotemporal dementia. Nat Rev Neurol 2016; 12: 175185.
99. Dale RC, Brilot F. Autoimmune basal ganglia disorders. J Child Neurol 2012; 27: 1470-81.
100. Martino D, Chew NK, Mir P, Edwards MJ, Quinn NP, Bhatia KP. Atypical movement disorders in antiphospholipid syndrome. Mov Disord 2006; 21: 944-9.
101. Morris HR, Lees AJ. Primary antiphospholipid syndrome presenting as a corticobasal degeneration syndrome. Mov Disord 1999; 14: 530-2.
102. Milanov IG, Rashkov R, Baleva M, Georgiev D. Antiphospholipid syndrome and parkinsonism. Clin Exp Rheumatol 1998; 16: 623-4.
103. Milanov I, Bogdanova D. Antiphospholipid syndrome and dystonia–parkinsonism. A case report. Parkinsonism Relat Disord 2001; 7: 139-41.
104. Reitblat T, Polishchuk I, Dorodnikov E, et al. Primary antiphospholipid antibody syndrome masquerading as progressive supranuclear palsy. Lupus 2003; 12: 67-9.
105. Chen WH, Lin HS, Kao YF, Lan MY, Liu JS. Postoperative parkinsonism and lupus anticoagulant: a model of autoantibodymediated neurotoxicity in stress. Brain Inj 2007; 21: 539-43.
106. Fahn S, Jankovic J, Hallett M. Principles and practice of movement disorders. 2nd ed. Elsevier Health Sciences 2011.
107. Bakdash T, Cohen AR, Hempel JM, Hoagland J, Newman AJ. Moyamoya, dystonia during hyperventilation, and antiphospholipid antibodies. Pediatr Neurol 2002; 26: 157-60.
108. Nardocci N, Zorzi G, Grisoli M, Rumi V, Broggi G, Angelini L. Acquired hemidystonia in childhood: a clinical and neuroradiological study of thirteen patients. Pediatr Neurol 1996; 15: 108-13.
109. Arena JE, Rabinstein AA. Transient global amnesia. Mayo Clin Proc 2015; 90(2): 264-72.
110. Mejia-Romero R, Garcia-Carrasco M, Galarza-Maldonado C, et al. Primary antiphospholipid syndrome in Latin American mestizo patients: clinical and immunologic characteristics and comparison with European patients. Clin Rheumatol 2008; 27: 891-7.
111. Ortego-Centeno N, Callejas-Rubio JL, Fernandez MG, Camello MG. Transient global amnesia in a patient with high and persistent levels of antiphospholipid antibodies. Clin Rheumatol 2006; 25: 407-8.
112. Van Roie E, Labarque V, Renard M, Van Geet C, Gabriels L. Obsessive-compulsive behavior as presenting symptom of primary antiphospholipid syndrome. Psychosom Med 2013; 75: 326-30.
113. Lyon G, Fattal-Valevski A, Kolodny EH. Leukodystrophies: clinical and genetic aspects. Top Magn Reson Imaging 2006; 17: 219-42.
114. di Poggio MB, Murdaca G, Puppo F, Primavera A. Antiphospholipid syndrome and reversible posterior Leukoencephalophaty Syndrome. Semin Arthritis Rheum 2010; 40: e9-10.
115. Salsano E, Chiapparini L, Finocchiaro G, Pareyson D, Savoiardo M. Adult-onset leukoencephalopathy with calcifications associated with primary antiphospholipid syndrome. J Neurol Neurosurg Psychiatry 2008; 79: 1215-7.
116. Neuwelt CM, Daikh DI, Linfoot JA, et al. Catastrophic antiphospholipid syndrome. Response to repeated plasmapheresis over three years. Arthritis Rheum 1997; 40: 1534-9.
117. Renard D, Dutray A, Le Quellec A, Milhaud D. Reversible posterior leukoencephalopathy syndrome in catastrophic antiphospholipid syndrome. Cerebrovasc Dis 2007; 24: 141-3.
118. King E, Odette W. Complex migraine with subtherapeutic INR in antiphospholipid syndrome. Am J Med 2012; 125: e9-10.
119. Hughes G, Cuadrado M, Khamashta M, Sanna G. Headache and memory loss: rapid response to heparin in the antiphospholipid syndrome. Lupus 2001; 10: 778.
120. Hughes G. Migraine, memory loss, and “multiple sclerosis”. Neurological features of the antiphospholipid (Hughes’) syndrome. Postgrad Med J 2003; 79: 81-3.
121. Asherson RA, Giampaulo D, Singh S, Sulman L. Dramatic response of severe headaches to anticoagulation in a patient with antiphospholipid syndrome. J Clin Rheumatol 2007; 13: 173-4.
122. Biernacka-Zielinska M, Lipinska J, Szymanska-Kaluza J, Stanczyk J, Smolewska E. Recurrent arterial and venous thrombosis in a 16-year-old boy in the course of primary antiphospholipid syndrome despite treatment with low-molecular-weight heparin: a case report. J Med Case Reports 2013; 7: 221.
123. Dandroo JM, Mohsin N, Nabi F. Antiphospholipid antibody syndrome presenting as transverse myelitis. Egypt Rheumatol Rehabil 2015; 42: 204-6.
124. Carter D, Olchovsky D, Yonath H, Langevitz P, Ezra D. Simultaneous deep vein thrombosis and transverse myelitis with negative serology as a first sign of antiphospholipid syndrome: a case report and review of the literature. Clin Rheumatol 2006; 25: 756-8.
125. Hoirisch-Clapauch S, Nardi AE. Psychiatric remission with warfarin: Should psychosis be addressed as plasminogen activator imbalance? Med Hypotheses 2013; 80: 137-41.
126. Taipa R, Santos E. Primary antiphospholipid antibody syndrome presenting with encephalopathy, psychosis and seizures. Lupus 2011; 20: 1433-5.
127. Karussis D, Leker RR, Ashekenazi A, Abramsky O. A subgroup of multiple sclerosis patients with anticardiolipin antibodies and unusual clinical manifestations: do they represent a new nosological entity? Ann Neurol 1998; 44: 629-34.
128. Frauenknecht K, Katzav A, Weiss Lavi R, et al. Mice with experimental antiphospholipid syndrome display hippocampal dysfunction and a reduction of dendritic complexity in hippocampal CA1 neurones. Neuropathol Appl Neurobiol 2015; 41: 657-71.
129. Frauenknecht K, Katzav A, Grimm C, Chapman J, Sommer CJ. Altered receptor binding densities in experimental antiphospholipid syndrome despite only moderately enhanced autoantibody levels and absence of behavioral features. Immunobiology 2014; 219: 341-9.
130. Katzav A, Grigoriadis NC, Ebert T, et al. Coagulopathy triggered autoimmunity: experimental antiphospholipid syndrome in factor V Leiden mice. BMC Med 2013; 11: 1-13.
131. Katzav A, Faust-Socher A, Kvapil F, et al. Antiphospholipid syndrome induction exacerbates a transgenic Alzheimer disease model on a female background. Neurobiol Aging 2011; 32: 272-9.
132. Menachem A, Chapman J, Katzav A. Hyperactivity induced by antiphospholipid syndrome serum. Ann NY Acad Sci 2009; 1173: 422-6.
133. Tanne D, Katzav A, Beilin O, et al. Interaction of inflammation, thrombosis, aspirin and enoxaparin in CNS experimental antiphospholipid syndrome. Neurobiol Dis 2008; 30: 56-64.
134. Ball-Rosen C, Primak-Rubinovicz H, Korczyn AD, et al. Identification of Histidine_Rich Glycoprotein, a Potential Autoantigen, in Human and Rat Brain Preparations. Ann NY Acad Sci 2007; 1109: 473-83.
135. Ziporen L, Polak-Charcon S, Korczyn DA, et al. Neurological dysfunction associated with antiphospholipid syndrome: histopathological brain findings of thrombotic changes in a mouse model. Clin Dev Immunol 2004; 11: 67-75.
136. Shoenfeld Y, Nahum A, Korczyn A, et al. Neuronal-binding antibodies from patients with antiphospholipid syndrome induce cognitive deficits following intrathecal passive transfer. Lupus 2003; 12: 436-42.
137. Shrot S, Katzav A, Korczyn A, et al. Behavioral and cognitive deficits occur only after prolonged exposure of mice to antiphospholipid antibodies. Lupus 2002; 11: 736-43.
138. Katzav A, Pick C, Korczyn A, et al. Hyperactivity in a mouse model of the antiphospholipid syndrome. Lupus 2001; 10: 496-9.
139. Ziporen L, Shoenfeld Y, Levy Y, Korczyn A. Neurological dysfunction and hyperactive behavior associated with antiphospholipid antibodies. A mouse model. J Clin Invest 1997; 100: 613-9.